Arbutus Biopharma Corporation ABUS Business Segments — Net Income (Loss)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's business segments — net income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's business segments — net income (loss)?
- Arbutus Biopharma Corporation (ABUS) reported business segments — net income (loss) of $169.7M in Q1 2026.
- How has Arbutus Biopharma Corporation's business segments — net income (loss) changed year-over-year?
- Arbutus Biopharma Corporation's business segments — net income (loss) increased by 791.9% year-over-year, from -$24.53M to $169.7M.
- What does business segments — net income (loss) mean?
- This is the bottom-line financial result for the specific business segment, calculated by subtracting all segment-related operating expenses from segment revenues. It indicates the profitability or burn rate of the segment's standalone activities.